As you all know i keep harping on about people connected to the markets and how we need to onboard someone of a high calibre in such a position
Well what i am about to highlight is a classic example of just that
most on here must have read what i previously posted on pepgen
well not being one to leave things at that i did a little more DD
so here goes
SO in 2020 an unlisted pepgen below
In December 2020, PepGen raised $45M Series A funding from RA Capital Management, Oxford Sciences Innovation (OSI), and Cure Duchenne Ventures to target rare diseases including Duchenne muscular dystrophy.
all good
Then on 4 feb 2021 some two months later
BOSTON and OXFORD, England, Feb. 4, 2021 /PRNewswire/ -- PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the enhanced delivery of therapeutic oligonucleotides, today announced the appointment of James McArthur, Ph.D., as President and Chief Executive Officer (CEO). Dr. McArthur brings more than 25 years of experience as a co-founder of numerous biotech companies focused on rare disease therapeutics. He joins the PepGen team at a time of rapid growth following its successful $45 million Series A financing at the end of 2020, which was led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), CureDuchenne Ventures, and the University of Oxford.
So James Mcarthur joins pepgen as CEO following its succesful $45million funding which was led by RA Capital Management
But theirs more
Dr. McArthur joins PepGen from RA Capital Management, where he served as a Venture Partner
Dr. McArthur has held senior research leadership roles at several gene and stem cell therapy companies as well as advisor roles at a number of venture capital firms.
"On behalf of the entire Board of Directors, I'm thrilled to welcome James to the PepGen team," said Ramin Farzaneh-Far, M.D., Venture Partner at RA Capital Management and PepGen's Executive Chairman.
The company is poised to unlock previously unachievable treatment strategies across a broad range of indications, and we are excited to have James join for the next chapter of PepGen's journey."
PepGen raised a $45 million Series A in December 2020 with RA Capital Management as the lead investor; Oxford Sciences Innovation (OSI)
Well well
Then by Dec 31 2021 some ten months later James McArthur ceo of pepgen had guided them through his association with RA Capital Management to the book below
PepGen has booked fair market value investment of $165.2 million as of December 31, 2021, from investors including RA Capital, Oxford Science Enterprises and KAVRA 16 LLC.
Now some might be happy to wait 20 years + and blame the markets this and blame that and we should be patient this etc etc
We have a company i have talked about above that has just raised $150 mil Au on the back of a Ph 1 study into DMD and previously on top of that raised $45mil
I think we can safely say that James McArthurs association with RA capital put him where he is
and
RA capitals associated investor relations put pepgen where they are today listed on the nasdaq with a single ph1 trial in DMD sat on a $12.00 stock and a $287mil MC
Very nice thank you very much
So you see my argument being, right people onboard connected to the markets a company can prosper
pepgen
1st patient dosed in ph1 trial
sat on a $12.00 stock and a $287mil MC
Look at our so called pipeline
ANP
Succesful Ph 2 rrms
Succesful Ph 2 Acromegaly
Succesful Ph2 DMD
succseful animal studies in AML We demonstrate that ATL1102 can efficiently decrease CD49d expression in AML cell line in vitro and in vivo, and that ATL1102 leads to mobilization of AML cells to the peripheral blood.
Succesful recent study for LGMD
upcoming results for long covid
RPDD voucher if dmd makes it to market prior to september 2026 ( value $60 - $350mil )
Yet we here we sit on a MC of just $56mil
Yes i paid attention to this latest chat on spark + and all i ever here is potential this and potential that
look at the pipeline we have more potential than you can poke a stick at
What we do not have and what appears to be a taboo subject to even talk about is the actual funding that is going to bring out all this potential, potential will not elevate this stock, i think that's a given by now
IMHO we need $70mil upfront prior to futility
As noted at the Company’s 2021 Annual General Meeting, the additional funding may be accessed through equity, debt via a loan or convertible instrument, partnering and collaboration initiatives or a mix thereof. The Company will update the market upon confirmation of such additional funding. The Company has also made an application to a government investment program for funding of the clinical trial and will advise the market should its application be successful.
December 2021 was the AGM which the above keeps referring us back to, is this really acceptable
So i ask
Are we being held up for that very same reason i have just pointed out above, complete lack of association with the right people that can make things actually happen
I believe 100% that we are, take that however you read it
Expand
(20min delay)
